信立泰：SAL0137药品临床试验申请获受理

Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial application of its innovative small molecule drug SAL0137, which is intended for the treatment of elevated lipoprotein (a) levels [1] Group 1 - The clinical trial application for SAL0137 has been accepted, indicating progress in the drug development process [1] - SAL0137 is a proprietary oral small molecule drug developed by the company [1] - The application specifically targets the treatment of elevated lipoprotein (a), a significant health concern [1]